chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pain, Injection site swelling
Clinical narrative: I have redness, swelling, and pain in that area; I have redness in that area; I have swelling in that area; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 15-JUN-2023, the patient received Shingles vaccine. On 16-JUN-2023, 1 days after receiving Shingles vaccine, the patient experienced injection site pain (Verbatim: I have redness, swelling, and pain in that area), injection site erythema (Verbatim: I have redness in that area) and injection site swelling (Verbatim: I have swelling in that area). The outcome of the injection site pain, injection site erythema and injection site swelling were not resolved.   It was unknown if the reporter considered the injection site pain, injection site erythema and injection site swelling to be related to Shingles vaccine.     It was unknown if the company considered the injection site pain, injection site erythema and injection site swelling to be related to Shingles vaccine.   Additional Information: GSK Receipt date: 16-JUN-2023 A reporter reported about a patient who received Shingles vaccine yesterday and today on the day of reporting the patient experienced redness, swelling and pain in that area.  Patient wanted to know how long should she/he expect that to last this adverse event.
Sex: F
Vaccine: VARZOS
Symptoms: Joint range of motion decreased, Pain
Clinical narrative: Shingrix - Arm decreased range of motion; Shingrix - Dull ache; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of joint range of motion decreased in a 72-year-old female patient who received Herpes zoster (Shingrix) (batch number 3922H, expiry date 17-FEB-2024) for prophylaxis.   In JAN-2023, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced joint range of motion decreased (Verbatim: Shingrix - Arm decreased range of motion) and pain (Verbatim: Shingrix - Dull ache). The outcome of the joint range of motion decreased and pain were unknown.   It was unknown if the reporter considered the joint range of motion decreased and pain to be related to Shingrix.     It was unknown if the company considered the joint range of motion decreased and pain to be related to Shingrix.   Additional Information: GSK Receipt date: 12-JUN-2023 Reporter Stated that the Adverse event started after the patient received the Shingrix dose but he did not mentioned the exact date of the onset. The reporter consented to follow up.
Age: 72.0
Sex: M
Vaccine: VARZOS
Symptoms: Bedridden, Fatigue, Gait disturbance
Clinical narrative: fatigue; patient cannot walk very well; barely get out of bed 5 days after it; This non-serious case was reported by a other health professional via call center representative and described the occurrence of bedridden in a 72-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included chronic fatigue.   On 20-MAY-2023, the patient received the 1st dose of Shingrix. In MAY-2023, an unknown time after receiving Shingrix, the patient experienced bedridden (Verbatim: barely get out of bed 5 days after it). On an unknown date, the patient experienced fatigue (Verbatim: fatigue) and walking difficulty (Verbatim: patient cannot walk very well). The outcome of the bedridden was resolved (duration 5 days) and the outcome of the fatigue and walking difficulty were not resolved.   It was unknown if the reporter considered the bedridden, fatigue and walking difficulty to be related to Shingrix.     It was unknown if the company considered the bedridden, fatigue and walking difficulty to be related to Shingrix.   Additional Information: GSK Receipt Date: 13-JUN-2023 The reporter reported that patient received a dose of Shingrix and can barely get out of bed 5 days after it. The patient could not walk very well due to fatigue. The vaccine was administered at an unknown pharmacy.
Age: 46.0
Sex: F
Vaccine: HEPA
Symptoms: Inappropriate schedule of product administration, Product administered to patient of inappropriate age, Underdose
Clinical narrative: Late second dose of Havrix; Havrix pediatric administered to the adult patient; Havrix pediatric administered to the adult patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 46-year-old female patient who received HAV (Havrix pediatric) (batch number F3Y25, expiry date 15-FEB-2025) for prophylaxis.   Previously administered products included Hepatitis A vaccine (1st dose received on 29th March 2016).   On 08-JUN-2023, the patient received the 2nd dose of Havrix pediatric. On 08-JUN-2023, an unknown time after receiving Havrix pediatric, the patient experienced drug dose administration interval too long (Verbatim: Late second dose of Havrix), underdose (Verbatim: Havrix pediatric administered to the adult patient) and adult use of a child product (Verbatim: Havrix pediatric administered to the adult patient). The outcome of the drug dose administration interval too long, underdose and adult use of a child product were unknown.   Additional Information: GSK Receipt Date: 15-JUN-2023 The reporter reported that the patient received late dose of Hepatitis A vaccine. The patient stated that it was unknown if the first dose was Havrix vaccine or other Hepatitis A vaccine. The vaccine administration facility was the same as primary reporter. The patient received 2nd dose of Havrix late than recommended time frame, which led to lengthening of vaccination schedule. The adult patient by mistakenly administered a pediatric dose of Havrix , which led to underdose and adult use of a child product. The reporter did consent to follow up. The case US2023084478 is identified as duplicate of case US2023084480. All future correspondence would be added in case US2023084480, which stands as case of record for this patient and the case US2023084478 would be deleted.
Age: 0.33
Sex: F
Vaccine: DTAPIPV
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: maladministration of kinrix as a 4 months old patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 4-month-old female patient who received DTPa-IPV (Kinrix) for prophylaxis.   On an unknown date, the patient received Kinrix. On an unknown date, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: maladministration of kinrix as a 4 months old patient). The outcome of the inappropriate age at vaccine administration was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 15-JUN-2023 The reporter consented to follow up. 4 month old patient received Kinrix (maladministration), which led to inappropriate age at vaccine administration.
Sex: F
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: Shingrix  Possible late 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 75-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on January 13th 2023 or October 17th 2019).   On an unknown date, the patient did not receive  the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: Shingrix  Possible late 2nd dose). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date:16-JUN-2023 The pharmacist reported that a patient received a dose of Shingrix on January 13th 2023 and was due for the second dose today (June 16th 2023, not administered). The insurance informed that patient had received a previous dose on October 17th, 2019, but patient does not remember the administration. Mentioned that due to covid situation probably was never administered.  Safety information on a possible The reporter did not consent to follow up. Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination. Note: The date for 1st dose was not confirmed however by assuming 2019 2nd dose was kept as incomplete course of vaccination.
Age: 18.0
Sex: F
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation issue
Clinical narrative: mixed 2 diluent of Menveo without the powder portion; ixed 2 diluent of Menveo (without the powder portion) and administered it to a patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a 18-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMXA977A, expiry date OCT-2025) for prophylaxis.   On 16-JUN-2023, the patient received Menveo. On 16-JUN-2023, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: mixed 2 diluent of Menveo without the powder portion) and inappropriate dose of vaccine administered (Verbatim: ixed 2 diluent of Menveo (without the powder portion) and administered it to a patient). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 16-JUN-2023 The Pharmacist mixed 2 diluent of Menveo (without the powder portion) and administered it to a patient which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter consented to follow up.
Age: 20.0
Sex: F
Vaccine: HEP
Symptoms: Accidental underdose, Product administered to patient of inappropriate age, Viral titre
Clinical narrative: Accidental underdose; an adult patient had inadvertently received a pediatric dose of Engerix-B; This non-serious case was reported by a nurse via call center representative and described the occurrence of accidental underdose in a 20-year-old female patient who received HBV (Engerix B pediatric) (batch number 333M4, expiry date 07-APR-2024) for prophylaxis.   On 16-JUN-2023, the patient received Engerix B pediatric. On 16-JUN-2023, an unknown time after receiving Engerix B pediatric, the patient experienced accidental underdose (Verbatim: Accidental underdose) and adult use of a child product (Verbatim: an adult patient had inadvertently received a pediatric dose of Engerix-B). The outcome of the accidental underdose and adult use of a child product were unknown.   Additional Information: GSK Receipt Date: 16-JUN-2023 The nurse called to inform that earlier that day an adult patient had inadvertently received a pediatric dose of Engerix B, which led to accidental underdose and adult use of a child product.  According to the nurse, it was the first dose of the second scheme of the patient since according to a titers test, the patient was not immune. The reporter consented to follow up.
Age: 71.0
Sex: M
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: administered an expired dose of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 71-year-old male patient who received HAV (Havrix) (batch number NZ7GR, expiry date 17-JUN-2023) for prophylaxis.   On 19-JUN-2023, the patient received Havrix. On 19-JUN-2023, an unknown time after receiving Havrix, the patient experienced expired vaccine used (Verbatim: administered an expired dose of Havrix). The outcome of the expired vaccine used was unknown.   Additional Information: GSK receipt date: 20-JUN-2023 Follow-up ok, HCP facility address and email are in HCP details. The reporter consented to follow up. The patient received an expired dose of Havrix, which led to expired vaccine used
Age: 24.0
Sex: F
Vaccine: TDAP
Symptoms: Expired product administered
Clinical narrative: Boostrix - Expired dose administration.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 24-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number 4M2EZ, expiry date 03-JUN-2023) for prophylaxis.   On 19-JUN-2023, the patient received Boostrix. On 19-JUN-2023, an unknown time after receiving Boostrix, the patient experienced expired vaccine used (Verbatim: Boostrix - Expired dose administration.). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 20-JUN-2023 The reporter asked for the efficacy of the expired vaccine. The reporter consented to follow up via email. The patient received an expired Boostrix, which led to expired vaccine used.
Age: 63.0
Sex: F
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: Expired dose given; This non-serious case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 63-year-old female patient who received HAV (Havrix) (batch number 63Y6M, expiry date 17-JUN-2023) for prophylaxis.   On 20-JUN-2023, the patient received the 2nd dose of Havrix. On 20-JUN-2023, an unknown time after receiving Havrix, the patient experienced expired vaccine used (Verbatim: Expired dose given). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 20-JUN-2023 The reporter reported that a patient received an expired dose of Havrix and wished to know how to proceed.  The information about the vaccine, patient and event given. medical information relayed. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up.  The patient received an expired dose of Havrix, which led to expired vaccine used.
Age: 18.0
Sex: M
Vaccine: DTAP
Symptoms: Expired product administered
Clinical narrative: dose of Infanrix was given today after it was expired; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 18-year-old male patient who received DTPa (Infanrix) (batch number 7km94, expiry date 10-JUN-2023) for prophylaxis.   On 20-JUN-2023, the patient received Infanrix. On 20-JUN-2023, an unknown time after receiving Infanrix, the patient experienced expired vaccine used (Verbatim: dose of Infanrix was given today after it was expired). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 20-JUN-2023 The reporter was a medical assistant. The reporter did not consent to follow-up. The reporter stated that Infanrix was given after it was expired, which led to expired vaccine used.
Sex: U
Vaccine: FLUX
Symptoms: Near death experience
Clinical narrative: almost loss my life; This serious case was reported by a consumer via interactive digital media and described the occurrence of near death experience in a patient who received Flu unspecified (Flu vaccine) for prophylaxis.   On an unknown date, the patient received Flu vaccine. On an unknown date, an unknown time after receiving Flu vaccine, the patient experienced near death experience (Verbatim: almost loss my life) (serious criteria GSK medically significant and life threatening). The outcome of the near death experience was not reported.   It was unknown if the reporter considered the near death experience to be related to Flu vaccine.     It was unknown if the company considered the near death experience to be related to Flu vaccine.   Additional Information: GSK Receipt Date: 21-JUN-2023 This case was reported the patient via interactive digital media. It was reported that vaccine were so dangerous that patient almost loss his/her life in 2018 from his/her first time ever flu vaccine. Follow-up not possible as no contact details provided.
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023.; No adverse event; 12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date), PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023.) and NO ADVERSE EVENT (No adverse event) in an adult male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7147B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-Jun-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023.) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date), PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date) and PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023.).    No relevant concomitant medications were reported. Vial size was 2.5 ml. Date the vial was initially stored in the refrigerator was on 12 Jun 2023. The vial haven't undergone any temperature excursions. No treatment medication reported.  This case contains information for the 11th of 12 patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-729389 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2023: Follow-up information included no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729389:Master case
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023.; No adverse event; 12 adult patients received expired Bivalent Moderna COVID-19 vaccine beyond MFG expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine beyond MFG expiration date), PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023. ) and NO ADVERSE EVENT (No adverse event) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7147B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-Jun-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine beyond MFG expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023. ) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine beyond MFG expiration date), PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023. ) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine beyond MFG expiration date) and PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023. ).    No relevant concomitant medications were reported. Vial size was 2.5 ml. Date the vial was initially stored in the refrigerator was on 12 Jun 2023. The vial haven't undergone any temperature excursions. No treatment medication reported.  This case contains information for the 12th of 12 patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-729389 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2023: Follow-up information included no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729389:Master case
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023.; No adverse event; 12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date), PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023. ) and NO ADVERSE EVENT (No adverse event) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7147B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Jun-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-Jun-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023. ) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date), PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023. ) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (12 adult patients received expired Bivalent Moderna COVID-19 vaccine on 12JUN2023 beyond MFG expiration date) and PRODUCT STORAGE ERROR (Vaccine was administered on 12 Jun 2023 and was expired on 17 May 2023. ).    No relevant concomitant medications were reported. Vial size was 2.5 ml. Date the vial was initially stored in the refrigerator was on 12 Jun 2023. The vial haven't undergone any temperature excursions. No treatment medication reported.  This case contains information for the 8th of 12 patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-729389 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2023: Follow up received contains No New Information; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729389:Master case
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023; No adverse event; 9 patients received vaccine after the 30 day BUD between 06-JUN-2023 to 09-JUN-2023.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30 day BUD between 06-JUN-2023 to 09-JUN-2023.), PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7185B) for COVID-19 prophylaxis.     No Medical History information was reported.    In June 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In June 2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30 day BUD between 06-JUN-2023 to 09-JUN-2023.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30 day BUD between 06-JUN-2023 to 09-JUN-2023.), PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30 day BUD between 06-JUN-2023 to 09-JUN-2023.) and PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023).    No concomitant medication was reported.  Dose was placed into the refrigerator initially on 04-MAY-2023. No treatment information was reported.  The case contains information for patient 3 out of 9.   This case was linked to US-MODERNATX, INC.-MOD-2023-729624 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729624:Master case
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023; No adverse event; Expired vaccine used; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used), PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7185B) for COVID-19 prophylaxis.     No Medical History information was reported.    In June 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In June 2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used), PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administred between 06-JUN-2023 to 09-JUN-2023).    No concomitant medication was reported.  Dose was placed into the refrigerator initially on 04-MAY-2023. No treatment information was reported.   This case contains information for patient 6 out of 9.   This case was linked to US-MODERNATX, INC.-MOD-2023-729624 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729624:Master case
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Dose was placed into the refrigerator initially on 4-MAY-2023 and administered between 06-JUN-2023 to 09-JUN-2023; No adverse event; 9 patients received vaccine after the 30-day BUD between 06-JUN-2023 to 09-JUN-2023.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30-day BUD between 06-JUN-2023 to 09-JUN-2023.), PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administered between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7185B) for COVID-19 prophylaxis.     No Medical History information was reported.    In June 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In June 2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30-day BUD between 06-JUN-2023 to 09-JUN-2023.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administered between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30-day BUD between 06-JUN-2023 to 09-JUN-2023.), PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administered between 06-JUN-2023 to 09-JUN-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30-day BUD between 06-JUN-2023 to 09-JUN-2023.) and PRODUCT STORAGE ERROR (Dose was placed into the refrigerator initially on 4-MAY-2023 and administered between 06-JUN-2023 to 09-JUN-2023).    No concomitant medication was reported.  Dose was placed into the refrigerator initially on 04-MAY-2023. No treatment information was reported. The case contains information for patient 4 out of 9.   This case was linked to US-MODERNATX, INC.-MOD-2023-729624 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729624:Master case
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Respiratory failure
Clinical narrative: RESPIRATORY FAILURE, UNSPECIFIED ACUITY
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Hypotension, Hypoxia
Clinical narrative: HYPOTENSION HYPOXIA
Age: 4.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoxia
Clinical narrative: HYPOXIA
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Laboratory test, No adverse event
Clinical narrative: I did not have an adverse reaction to the vaccine. In 08/2022, I started having pain in my left side and that just got worse and worse. I went to my doctor, and I was referred to a gastroenterologist. I have had multiply test and they don't know what is going on. I was given a list of things I can eat and not eat. Also I am taking medication to help digest my foood.
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: Amnesia, Memory impairment
Clinical narrative: DAUGHTER REPORTS MOM HAS SHORT TERM MEMORY LOSS. SHE STATES MOM WAS ABLE TO DAILY TAKE HER OWN VITAL SIGNS, WRITE CHECKS TO PAY HER BILLS, TAKE HER OWN MEDS. SHE BECAME FORGETFUL ON A TRIP THEY TOOK THE SAME DAY THE VACCINE WAS GIVEN, FORGETTING WHERE SHE WAS GOING AND WHY. SHE WAS ON THIS TRIP WITH HER TWO DAUGHTERS, ASKING WHERE SHE WAS AND WHY ARE WE GOING? DAUGHTER STATED SHE REACTED THE SAME WAY AFTER HAVING COVID AUGUST 2022 BUT THAT SHE IMPROVED TO THE POINT OF BEING ABLE TO AGAIN TAKE HER DAILY VITAL SIGNS, MEDS, AND PAY HER BILLS. DAUGHTER STATES HER MOM IS AWAITING NEUROLOGY APPOINTMENT. AS A RESULT OF HER MEMORY LOSS IN AUGUST AND SHE PLANS TO DISCUSS THIS RECENT MEMORY LOSS. DAUGHTER DID NOT SEEK IMMEDIATE MEDICAL CARE FOR HER MOM WHEN ACUTE MEMORY ISSUES WERE NOTICED ON JUNE 7, 2023.
Age: 87.0
Sex: M
Vaccine: COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 5 vaccines Moderna 2/9/21 lot# 032H20A;  Moderna 3/9/21 Lot# 011M20A;  MOdern 8/27/21 lot# 017E21A;  Pfizer 3/22/22 lot# FJ4991;  PFizer 9/15/22 lot# GJ5342
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Moderna 3/12/21 lot# 040A21A;  Modern a4/13/21 lot# 044B21A
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Expired vaccine used; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7185B) for COVID-19 prophylaxis.     No Medical History information was reported.    In June 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In June 2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Expired vaccine used).    No concomitant medication was reported.  Dose was placed into the refrigerator initially on 04-MAY-2023. No treatment information was reported.  This case contains information for patient 8 out of 9.   This case was linked to US-MODERNATX, INC.-MOD-2023-729624 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729624:Master case
Age: 57.0
Sex: F
Vaccine: COVID19-2
Symptoms: Hypoxia
Clinical narrative: HYPOXIA
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Moderna 10/25/21 lot# 012F21A;  Moderna 11/22/21 lot# 034F
Age: 96.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 3 vaccine Moderna 2/8/21 lot# 013M20A;  Moderna 3/8/21 lot# 030A21A;  Pfizer 11/15/21 lot# FH802
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Arthritis, Brain fog, Dyspnoea, Exercise tolerance decreased, Fatigue
Clinical narrative: Extreme fatigue, muscle weakness, brain fog. He cannot run any longer, he now has shortness of breath as well. He went from 8-10 miles a day, to not being able to run .5 mile. His heart beats very erratic heartbeat when he is trying to do cardio. You can see his heart beating outside of his shirt. Ortho stated that he has some kind of inflammation, then went to a rheumatologist and they stated that somehow, some temporary arthritis has been triggered. He also saw  Dr..
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Heart rate irregular, Inflammation, Laboratory test, Muscular weakness, Palpitations
Clinical narrative: Extreme fatigue, muscle weakness, brain fog. He cannot run any longer, he now has shortness of breath as well. He went from 8-10 miles a day, to not being able to run .5 mile. His heart beats very erratic heartbeat when he is trying to do cardio. You can see his heart beating outside of his shirt. Ortho stated that he has some kind of inflammation, then went to a rheumatologist and they stated that somehow, some temporary arthritis has been triggered. He also saw  Dr..
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Pfizer 3/27/21 lot# EN6202;  Pfizer 4/17/21 lot# ER8732
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Pfizer 3/22/21 lot# ER2613;  Pfizer 4/12/21 lot# Ew0150
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Hypotension, Hypoxia
Clinical narrative: HYPOTENSION ACUTE RESPIRATORY FAILURE HYPOXIA
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Vaccine was initially stored into refrigerator on 04-May-2023 and vaccine was administered between 6-Jun-2023 to 9-Jun-2023.; No adverse event; 9 patients received vaccine after the 30-day BUD between 6-Jun-2023 to 9-Jun-2023.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30-day BUD between 6-Jun-2023 to 9-Jun-2023.), PRODUCT STORAGE ERROR (Vaccine was initially stored into refrigerator on 04-May-2023 and vaccine was administered between 6-Jun-2023 to 9-Jun-2023.) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7185B) for COVID-19 prophylaxis.     No Medical History information was reported.    In June 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In June 2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30-day BUD between 6-Jun-2023 to 9-Jun-2023.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was initially stored into refrigerator on 04-May-2023 and vaccine was administered between 6-Jun-2023 to 9-Jun-2023.) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30-day BUD between 6-Jun-2023 to 9-Jun-2023.), PRODUCT STORAGE ERROR (Vaccine was initially stored into refrigerator on 04-May-2023 and vaccine was administered between 6-Jun-2023 to 9-Jun-2023.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (9 patients received vaccine after the 30-day BUD between 6-Jun-2023 to 9-Jun-2023.) and PRODUCT STORAGE ERROR (Vaccine was initially stored into refrigerator on 04-May-2023 and vaccine was administered between 6-Jun-2023 to 9-Jun-2023.).    Concomitant product use was not provided by the reporter.  Suspect dosage text was reported as unknown.  No additional doses medications or treatments administered in response.  Treatment information was not provided.  This case contains information about patient 9th out of 9 adult patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-729624 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-729624:Master case
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Pfizer 1/26/21 Lot# El3248;  Pfizer 2/16/21 lot# EL3249
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Confusional state, Death, SARS-CoV-2 test positive, Unresponsive to stimuli
Clinical narrative: Patient was admitted to Medical Center on 06-09-2023 from Hospital due to unresponsiveness and confusion. Was d/c'd on 06-19-2023 and admitted to hospice on 06-19-2023 The patient expired on 06-20-23 at 8:23pm.? Patient was Covid positive on 06-14-2023
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Moderna 4/14/21 lot# 044B21A;  Moderna 5/12/21 lot# 034C21A
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Angina pectoris
Clinical narrative: STABLE ANGINA ANGINA, UNSPECIFIED
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Joint stiffness, Joint swelling, No adverse event, Pain in extremity
Clinical narrative: I did not have an adverse reaction to the vaccine. In 03/2023, I woke up unable to close my hands. I have swollen joints and pain in both hands. I have seen my doctor and I have referred to a specialist.  I take two Advil each night before going to bed.
Age: 26.0
Sex: M
Vaccine: YF
Symptoms: Expired product administered, No adverse event
Clinical narrative: Expired vaccine administered to patient. Expiration date: 21JUL2022. Patient, 6hr post administration, is not feeling any adverse reactions.
Age: 79.0
Sex: M
Vaccine: COVID19-2
Symptoms: Angina pectoris, Symptom recurrence
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ANGINA, UNSPECIFIED 11/15/2022 -- RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 59.0
Sex: F
Vaccine: VARZOS
Symptoms: Asthenia, Electric shock sensation, Feeling abnormal, Headache, Induration
Clinical narrative: Day 1, I was able to do my morning walk, but soon after I started feeling sluggish and achy. I developed a bad headache and had a lot of symptoms similar to the flu, but no fever. My arm had a knot the size of a hardball, and just as hard, and feverish. I was able to go to work, but felt bad the entire day. Day 2, I felt much, much better, but the knot, soreness and fever were still there. I kept the knot, pain and fever for about a week total. As the days passed the knot got itchy, but no rash, until it was gone. At first it was too painful to scratch, but as the pain subsided each day I'd just massage the itch. About 10 days after taking the vaccine I developed an itchy neck and face. The front of my throat and face would get randomly itchy at all times of the day and night. No visible rash, only itchy. This continued every day. I only realized it was a reaction from the shot when I got in the shower at about day 13 or 14, and the water felt like little shots of electricity on my neck. This is the same way my husband described it when he had shingles about 24 years ago. That must have been the peak, because since that day all the itchiness seems to have lessened a little at a time. Today, at day 23, I still have some itching, but not nearly as bad as it was. I haven't regained my regular level of energy back either. I'm hoping that will return soon.
Age: 59.0
Sex: F
Vaccine: VARZOS
Symptoms: Influenza, Nodule, Pain, Pain in extremity, Pruritus
Clinical narrative: Day 1, I was able to do my morning walk, but soon after I started feeling sluggish and achy. I developed a bad headache and had a lot of symptoms similar to the flu, but no fever. My arm had a knot the size of a hardball, and just as hard, and feverish. I was able to go to work, but felt bad the entire day. Day 2, I felt much, much better, but the knot, soreness and fever were still there. I kept the knot, pain and fever for about a week total. As the days passed the knot got itchy, but no rash, until it was gone. At first it was too painful to scratch, but as the pain subsided each day I'd just massage the itch. About 10 days after taking the vaccine I developed an itchy neck and face. The front of my throat and face would get randomly itchy at all times of the day and night. No visible rash, only itchy. This continued every day. I only realized it was a reaction from the shot when I got in the shower at about day 13 or 14, and the water felt like little shots of electricity on my neck. This is the same way my husband described it when he had shingles about 24 years ago. That must have been the peak, because since that day all the itchiness seems to have lessened a little at a time. Today, at day 23, I still have some itching, but not nearly as bad as it was. I haven't regained my regular level of energy back either. I'm hoping that will return soon.
Age: 59.0
Sex: F
Vaccine: VARZOS
Symptoms: Pyrexia, Sluggishness, Throat irritation
Clinical narrative: Day 1, I was able to do my morning walk, but soon after I started feeling sluggish and achy. I developed a bad headache and had a lot of symptoms similar to the flu, but no fever. My arm had a knot the size of a hardball, and just as hard, and feverish. I was able to go to work, but felt bad the entire day. Day 2, I felt much, much better, but the knot, soreness and fever were still there. I kept the knot, pain and fever for about a week total. As the days passed the knot got itchy, but no rash, until it was gone. At first it was too painful to scratch, but as the pain subsided each day I'd just massage the itch. About 10 days after taking the vaccine I developed an itchy neck and face. The front of my throat and face would get randomly itchy at all times of the day and night. No visible rash, only itchy. This continued every day. I only realized it was a reaction from the shot when I got in the shower at about day 13 or 14, and the water felt like little shots of electricity on my neck. This is the same way my husband described it when he had shingles about 24 years ago. That must have been the peak, because since that day all the itchiness seems to have lessened a little at a time. Today, at day 23, I still have some itching, but not nearly as bad as it was. I haven't regained my regular level of energy back either. I'm hoping that will return soon.